HMGCR and kidney cancer: This result was directionally consistent with a recent MR study of 1,310 kidney cancer patients from UK Biobank, which found that genetically proxied inhibition of HMGCR was not associated with RCC risk [OR = 1.35 [95% CI, 0.51–3.57], P = 0.554] (39).